Collaborations & Alliances

Genmab, Janssen Partner for Next-Gen CD38 Antibody

To collaborate on HexaBody-CD38, a next-generation CD38 antibody product incorporating Genmab's HexaBody technology

Genmab has signed an agreement with Janssen Biotech, Inc. to collaborate exclusively on a next-generation CD38 antibody product, HexaBody®-CD38, incorporating Genmab’s HexaBody technology. The new agreement builds on Genmab’s successful DARZALEX® collaboration with Janssen. HexaBody-CD38 could potentially add to the DARZALEX multiple myeloma franchise and expand the potential of CD38-targeted therapies in further indications. For HexaBody-CD38, Genmab obtained promising pre-clinical data in a pa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters